Medical Developments International (ASX:MVP) Other Long-Term Liabilities: A$1.74 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MVP Medical Developments International Ltd ASX:MVP
46 GF Score
Price A$0.49
GF Value A$0.62
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International Other Long-Term Liabilities?

Medical Developments International ASX:MVP -1.02% 46 Other Long-Term Liabilities is A$1.74 Mil as of Dec. 2025. GuruFocus rates ASX:MVP with a GF Score™ of 46/100 and a GF Value™ of A$0.62 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Medical Developments International's other long-term liabilities for the quarter that ended in Dec. 2025 was A$1.74 Mil.

Medical Developments International's quarterly other long-term liabilities declined from Dec. 2024 (A$1.86 Mil) to Jun. 2025 (A$-0.00 Mil) but then increased from Jun. 2025 (A$-0.00 Mil) to Dec. 2025 (A$1.74 Mil).

Medical Developments International's annual other long-term liabilities declined from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$-0.00 Mil) but then increased from Jun. 2024 (A$-0.00 Mil) to Jun. 2025 (A$-0.00 Mil).

Medical Developments International Other Long-Term Liabilities Related Terms

Medical Developments International Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Medical Developments International's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International Other Long-Term Liabilities Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 -0.00

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 -0.00 1.86 -0.00 1.74
ASX:MVP
46GF Score
Medical Developments International Ltd ASX:MVP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Developments International Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$1.74 Mil mean?
Medical Developments International (ASX:MVP) has a Other Long-Term Liabilities of A$1.74 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medical Developments International and its competitors.
Is Medical Developments International's Other Long-Term Liabilities too high?
Medical Developments International's current Other Long-Term Liabilities is A$1.74 Mil. Overall, Medical Developments International has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Other Long-Term Liabilities compare to ZTS?
Medical Developments International's Other Long-Term Liabilities of A$1.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medical Developments International and its competitors. Medical Developments International's current Other Long-Term Liabilities is A$1.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.62, compared to a current price of A$0.49 — trading 21.8% below its estimated fair value. The current Other Long-Term Liabilities is A$1.74 Mil. Medical Developments International's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current Other Long-Term Liabilities is A$1.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (ASX:MVP) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of A$0.49 is trading 21.8% below its estimated GF Value™ of A$0.62. GuruFocus considers Medical Developments International to be Modestly Undervalued.

Key valuation signals for ASX:MVP:

  • Other Long-Term Liabilities: A$1.74 Mil
  • GF Value™: A$0.62 vs. price of A$0.49 (21.8% below fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAM5D:Germany
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
46GF Score

Get the complete analysis for ASX:MVP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.49
Price
A$0.62
GF Value